Over the past decade, immune checkpoint blockade (ICB) therapy has revolutionized the
outlook for oncology with significant and sustained improvement in the overall patient …

Simple Summary In this manuscript, we discuss recent updates on melanoma-related
clinical trial data. We explore diverse topics, including new therapeutic agents and novel …

Immune checkpoint blocking antibodies are a cornerstone in cancer treatment; however,
they benefit only a subset of patients and biomarkers to guide immune checkpoint blockade …

Original research: Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and
TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas - PMC Back …

Background. As the number and proportion of lymphocyte subsets are an important indicator
of the immune function, an in depth understanding of the immune function of patients with …

Purpose: Preclinical data suggest that radiotherapy (RT) is beneficial in combination with
immune checkpoint blockade. Clinical trials have explored RT with single-agent immune …

Objectives Evaluate outcomes of patients with recurrent or metastatic (R/M) head and neck
squamous cell carcinoma (HNSCC) treated with immunotherapy (IO). Methods Among …

Background The absolute count of lymphocyte subsets (ACLS) is correlated to the prognosis
of multiple malignancies. This study aimed to combine the ACLS with the clinicopathological …

It is well-known that inflammation plays a significant role in cancer formation and prognosis.
Both lymphocyte count and red cell distribution width (RDW) has been used to predict …

Nivolumab and ipilimumab (NIVO+ IPI) is standard therapy for patients with advanced renal
cell carcinoma (RCC). Absolute lymphocyte count (ALC) is a valuable prognostic factor in …